Answers are grounded in this paper and cite their sources.
The use of biological agents is expanding worldwide as a new treatment alternative for chronic inflammatory diseases including more recently skin diseases, especially psoriasis. Although frequently observed, the knowledge about acute and chronic dermatological adverse events is limited, and potential pathogenic mechanisms still have to be identified. Exact diagnosis is required considering that dermatological adverse events raise a decisional challenge about potential treatment discontinuation. The object of this publication is to present an overview of the dermatological adverse events of these new treatment alternatives.
No takes yet. Share an insight, caveat, or question.
Thielen et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: